
Tenet Healthcare (THC) Stock Forecast & Price Target
Tenet Healthcare (THC) Analyst Ratings
Bulls say
Tenet Healthcare's positive outlook is bolstered by its continued investment in the USPI segment, which is characterized by faster growth, higher margins, and improved returns. The company anticipates a steady increase in return on invested capital (ROIC), underpinned by strong demand, a favorable payer mix, and effective cost management initiatives, contributing to enhanced visibility into margin expansion. The ongoing transformation within Tenet's operations, especially through the USPI segment, positions it for significant financial advancements in the coming years.
Bears say
Tenet Healthcare's stock faces a negative outlook due to substantial potential headwinds from subsidy expirations, estimated at $220 million for its Acute segment and $30 million for its United Surgical Partners International (USPI) segment, which are projected to impact the 2026 financial forecast significantly. Additionally, the anticipated 20% decline in Health Insurance Exchange (HIX) coverage may lead to 80-85% of affected individuals becoming uninsured, resulting in decreased utilization of healthcare services. While Tenet recorded a temporary boost from $148 million in non-recurring Medicaid state funds in 2025, this is seen as insufficient to counterbalance the looming structural challenges and financial pressures the company faces.
This aggregate rating is based on analysts' research of Tenet Healthcare and is not a guaranteed prediction by Public.com or investment advice.
Tenet Healthcare (THC) Analyst Forecast & Price Prediction
Start investing in Tenet Healthcare (THC)
Order type
Buy in
Order amount
Est. shares
0 shares